Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a traditional chinese herbal granule boost stroke recovery?

NCT ID NCT07163702

Disease control Sponsor: Dongzhimen Hospital, Beijing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a traditional Chinese herbal medicine called Xinglou Chengqi Granule for people who recently had a stroke. Researchers want to find the best dose and see if it helps improve recovery. Sixty adults aged 18-70 with moderate stroke symptoms will receive either a high or low dose of the granules plus standard care. The main goal is to measure changes in stroke-related disability after 14 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Xinglou Chengqi Granule (herbal granules)
What this could lead to
If successful, this could point toward a new herbal treatment option to improve recovery after a stroke.
What could go wrong
This is an early phase 2a trial with only 60 participants, so results are preliminary. The herbal granules may not prove more effective than standard care, and side effects are not yet well understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Inpatients diagnosed with acute ischemic stroke. 2. Meet the criteria of TCM phlegm-heat and fu-organ excess syndrome. 3. Acute ischemic stroke within 7 days after onset. 4. 6 ≤ NIHSS \<20. 5. Aged 18-70 years, male or female. 6. The patient or representative has signed informed consent. Exclusion Criteria: 1. Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc. 2. NIHSS Ⅰa ≥2. 3. Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 ) 4. Received or planned thrombolysis or endovascular therapy after onset. 5. Known severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase \> 2.5 times the upper limit of normal value, serum creatinine \> 1.5 times the upper limit of normal value) 6. With cancers or uncontrolled diabetes. 7. The expected survival time is less than 3 months. 8. Patients who have used other traditional Chinese medicine for treating acute ischemic stroke since stroke onset. 9. Patients with severe mental disorders, dementia, or other comorbid diseases that may affect neurological function examination. 10. With a history of alcohol or drug abuse or drug dependence. 11. Those known to be allergic to the investigated drug or its components. 12. Pregnancy, potential pregnancy, or breastfeeding. 13. Currently participating in other clinical trials during the past 3 months. 14. Those who are judged by researchers to have poor compliance or are not suitable for participating in this study for any other reason.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dongzhimen Hospital, Beijing University of Chinese Medicine

    Richmond, British Columbia, V7E 6J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.